Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glutamic acid decarboxylase 2 (GAD2), also known as GAD65, is an enzyme that catalyzes the conversion of L-glutamic acid to gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the central nervous system. It is a key autoantigen in type 1 diabetes and implicated in other autoimmune diseases.
Catalyzes the conversion of L-glutamic acid to gamma-aminobutyric acid (GABA)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glutamic Acid Decarboxylase 2 (GAD65).